You're Exposed to Toxins Daily, Yet Your Body Can't Clear Them. Here's Why.

GSTM1 encodes a glutathione S-transferase enzyme responsible for tagging environmental toxins, pesticides, and heavy metals so your body can eliminate them through bile and urine. It’s one of your primary detoxification gates.

The problem: roughly 50% of the population carries the GSTM1 null genotype, meaning the entire gene is deleted. No deletion, no enzyme. People with the GSTM1 null mutation have a severely reduced capacity to clear benzene, pesticides, and other common environmental toxins. Your liver can activate them, but it cannot finish the job of eliminating them.

Without GSTM1, toxins circulate longer in your bloodstream and tissues. Heavy metals accumulate. Pesticide metabolites linger. Your mitochondria are exposed to oxidative stress longer than they should be. You feel this as fatigue, cognitive fog, and a general sense that your body is running in overdrive trying to clear something it cannot fully process.

GSTP1 is your second glutathione S-transferase, specializing in clearing oxidative stress byproducts and electrophiles created during phase I detoxification. It’s particularly important for neutralizing the reactive intermediates your liver creates when processing environmental chemicals.

The problem: the GSTP1 Ile105Val variant, carried by roughly 35 to 40% of the population, reduces enzyme activity and slows the clearance of oxidative stress byproducts. Your phase I enzymes are working fine (generating reactive intermediates), but phase II cannot keep up. These reactive molecules damage mitochondria, deplete glutathione, and trigger inflammatory cascades.

You experience this as unexplained fatigue, joint pain, and a vulnerability to chemical or environmental triggers that others seem unaffected by. Your body can activate toxins but struggles to neutralize and eliminate the reactive intermediates it creates in the process.

GSTT1 is your third glutathione S-transferase, with a specialized role: it clears halogenated compounds including chlorine, bromine, and fluorine containing chemicals. These include disinfection byproducts in tap water, brominated flame retardants in furniture, and certain pesticide metabolites.

The problem: roughly 15 to 20% of people with European ancestry carry the GSTT1 null genotype (entire gene deletion). Without GSTT1, your body cannot efficiently clear the specific class of halogenated toxins you encounter daily in water, textiles, and food. These compounds accumulate in fat tissue and the nervous system.

People with GSTT1 null often report heightened sensitivity to tap water, chlorine, and flame-retardant treated fabrics. Brain fog worsens after exposure to chlorinated pools. Fatigue deepens after drinking unfiltered tap water. You’re not imagining it; your detoxification pathway literally cannot process these compounds.

SOD2 encodes superoxide dismutase 2, an antioxidant enzyme that works inside your mitochondria to neutralize free radicals created during energy production. It’s your cells’ first line of defense against oxidative damage at the energy-producing level.

The problem: the SOD2 Val16Ala variant, carried by roughly 40% of people with European ancestry in the homozygous form, reduces the enzyme’s ability to scavenge superoxide radicals inside the mitochondria. When you’re exposed to environmental toxins, your mitochondria become overwhelmed. They produce excess free radicals. SOD2 cannot keep up. Oxidative stress accumulates faster than your body can neutralize it.

This manifests as relentless fatigue that doesn’t improve with rest, exercise intolerance, and vulnerability to toxic exposures that seem to trigger disproportionate exhaustion in you but not others. Your energy-producing cells are drowning in oxidative stress from toxin processing.

MTHFR catalyzes the conversion of folate into its active form, methylfolate, which is essential for methylation reactions throughout your body. One critical downstream effect: MTHFR activity determines how much glutathione your cells can produce, and glutathione is your primary heavy metal binder and detoxifier.

The problem: the MTHFR C677T variant, carried by roughly 40% of people with European ancestry, reduces enzyme efficiency and impairs glutathione production at the cellular level. Your cells cannot manufacture enough of the molecule that binds and eliminates mercury, lead, cadmium, and other heavy metals. You can reduce exposure, but you cannot efficiently clear what you’ve already accumulated.

People with MTHFR variants often report worsening brain fog and fatigue after starting typical B vitamin supplementation (which requires MTHFR to convert), or after exposure to heavy metals (which depletes the limited glutathione they can make). Heavy metal testing may show accumulation despite low current exposure.

NQO1 encodes NAD(P)H quinone oxidoreductase, a phase II enzyme that detoxifies a specific but important class of compounds: quinones (found in some medications and environmental chemicals), and benzene metabolites from exhaust and industrial exposure. It also helps neutralize oxidative stress byproducts.

The problem: the NQO1 Pro187Ser null variant, found in roughly 4 to 20% of the population depending on ancestry, completely eliminates NQO1 activity. People carrying this variant cannot process benzene, quinone-containing medications, or certain oxidative stress intermediates. Exposure to traffic exhaust, occupational benzene, or certain medications triggers disproportionate toxic accumulation.

If you carry the NQO1 null variant, you may notice that other people tolerate benzene-containing exposures (traffic, garage fumes) without issue, but you experience headaches, cognitive fog, or fatigue. Certain medications that are safe for most people trigger concerning side effects in you. Your body literally lacks the enzyme to process these compounds.